Merck-Mittel Bavencio verfehlt Endpunkt in Magenkrebs-Studie

08:49 EST 8 Nov 2019 | FinanzNachrichten

FRANKFURT (Dow Jones)--Der deutsche Pharmakonzern Merck und sein US-Partner Pfizer haben mit ihrem Medikament Bavencio (Wirkstoff Avelumab) einen Rückschlag erlitten. Eine klinische Phase-III-Stud...

Original Article: Merck-Mittel Bavencio verfehlt Endpunkt in Magenkrebs-Studie


More From BioPortfolio on "Merck-Mittel Bavencio verfehlt Endpunkt in Magenkrebs-Studie"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...